NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,692 | -21.4% | 2,377,978 | -0.1% | 0.00% | 0.0% |
| Q2 2023 | $23,776 | +3.6% | 2,379,873 | -7.9% | 0.00% | 0.0% |
| Q1 2023 | $22,954 | -35.7% | 2,584,751 | -20.6% | 0.00% | -50.0% |
| Q4 2022 | $35,726 | -99.9% | 3,253,736 | -9.8% | 0.01% | -25.0% |
| Q3 2022 | $46,991,000 | -19.7% | 3,606,352 | -22.0% | 0.01% | +14.3% |
| Q2 2022 | $58,546,000 | -13.1% | 4,620,823 | -3.9% | 0.01% | 0.0% |
| Q1 2022 | $67,336,000 | -52.3% | 4,806,289 | -1.3% | 0.01% | -46.2% |
| Q4 2021 | $141,018,000 | -0.3% | 4,871,084 | +3.2% | 0.01% | 0.0% |
| Q3 2021 | $141,378,000 | +31.5% | 4,718,877 | +16.5% | 0.01% | +30.0% |
| Q2 2021 | $107,486,000 | +11.8% | 4,051,478 | +31.0% | 0.01% | 0.0% |
| Q1 2021 | $96,183,000 | +394.4% | 3,093,705 | +422.9% | 0.01% | +400.0% |
| Q4 2020 | $19,453,000 | -1.0% | 591,636 | +5.1% | 0.00% | 0.0% |
| Q3 2020 | $19,645,000 | – | 562,746 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |